Belgium's UCB Is Almost Over Its Patent Cliff, But Guides Revenues And Profits To Decline In 2012
This article was originally published in The Pink Sheet Daily
Executive Summary
UCB Pharma's trio of new products is managing, for now, to compensate for the generic erosion to its best-selling anti-epileptic Keppra.